10x Genomics (TXG) Change in Accured Expenses (2018 - 2026)

10x Genomics has reported Change in Accured Expenses for 9 years, with the latest figure at -$613000.0 in Q1 2026.

• Quarterly Change in Accured Expenses changed N/A year-over-year to -$613000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.8 million (down 135.31% YoY) and the FY2025 annual result came in at -$5.2 million, down 241.02% from the prior year.
• Change in Accured Expenses grew to -$613000.0 in Q1 2026 per TXG's latest filing, from -$7.4 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $19.1 million in Q4 2023 and troughed at -$13.3 million in Q1 2022.
• A 5-year average of $1.7 million and a median of $2.2 million in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses jumped 651.57% in 2022, then plunged 7772.05% in 2024.
• Over 5 years, Change in Accured Expenses stood at $4.3 million in 2022, then jumped by 347.7% to $19.1 million in 2023, then plunged by 80.53% to $3.7 million in 2024, then sank by 299.44% to -$7.4 million in 2025, then soared by 91.76% to -$613000.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$613000.0, -$7.4 million, and $5.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.